191 related articles for article (PubMed ID: 31863639)
1. Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model.
Zalles M; Smith N; Ziegler J; Saunders D; Remerowski S; Thomas L; Gulej R; Mamedova N; Lerner M; Fung KM; Chung J; Hwang K; Jin J; Wiley G; Brown C; Battiste J; Wren JD; Towner RA
J Cell Mol Med; 2020 Jan; 24(2):1738-1749. PubMed ID: 31863639
[TBL] [Abstract][Full Text] [Related]
2. ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models.
Ziegler J; Pody R; Coutinho de Souza P; Evans B; Saunders D; Smith N; Mallory S; Njoku C; Dong Y; Chen H; Dong J; Lerner M; Mian O; Tummala S; Battiste J; Fung KM; Wren JD; Towner RA
Neuro Oncol; 2017 Feb; 19(2):175-185. PubMed ID: 27416955
[TBL] [Abstract][Full Text] [Related]
3. A tale of two multi-focal therapies for glioblastoma: An antibody targeting ELTD1 and nitrone-based OKN-007.
Zalles M; Smith N; Saunders D; Lerner M; Fung KM; Battiste J; Towner RA
J Cell Mol Med; 2022 Jan; 26(2):570-582. PubMed ID: 34910361
[TBL] [Abstract][Full Text] [Related]
4. Assessment of an scFv Antibody Fragment Against ELTD1 in a G55 Glioblastoma Xenograft Model.
Zalles M; Smith N; Saunders D; Saran T; Thomas L; Gulej R; Lerner M; Fung KM; Chung J; Hwang K; Jin J; Battiste J; Towner RA
Transl Oncol; 2020 Mar; 13(3):100737. PubMed ID: 32208341
[TBL] [Abstract][Full Text] [Related]
5. Targeting ELTD1, an angiogenesis marker for glioblastoma (GBM), also affects VEGFR2: molecular-targeted MRI assessment.
Ziegler J; Zalles M; Smith N; Saunders D; Lerner M; Fung KM; Patel M; Wren JD; Lupu F; Battiste J; Towner RA
Am J Nucl Med Mol Imaging; 2019; 9(1):93-109. PubMed ID: 30911439
[TBL] [Abstract][Full Text] [Related]
6. ELTD1 as a multi-focal target for malignant gliomas: preclinical studies.
Zalles M; Smith N; Saunders D; Guzman M; Lerner M; Fung KM; Babu A; Battiste J; Chung J; Hwang K; Jin J; Towner RA
Neurooncol Adv; 2021; 3(1):vdab132. PubMed ID: 34704036
[TBL] [Abstract][Full Text] [Related]
7. ELTD1 as a biomarker for multiple sclerosis: Pre-clinical molecular-targeted studies in a mouse experimental autoimmune encephalomyelitis model.
Towner RA; Smith N; Zalles M; Morris S; Toliver M; Saunders D; Lerner M; Kumar G; Axtell RC
Mult Scler Relat Disord; 2021 Apr; 49():102786. PubMed ID: 33517175
[TBL] [Abstract][Full Text] [Related]
8. ELTD1 deletion reduces vascular abnormality and improves T-cell recruitment after PD-1 blockade in glioma.
Huang H; Georganaki M; Conze LL; Laviña B; van Hooren L; Vemuri K; van de Walle T; Ramachandran M; Zhang L; Pontén F; Bergqvist M; Smits A; Betsholtz C; Dejana E; Magnusson PU; He L; Lugano R; Dimberg A
Neuro Oncol; 2022 Mar; 24(3):398-411. PubMed ID: 34347079
[TBL] [Abstract][Full Text] [Related]
9. ELTD1, a potential new biomarker for gliomas.
Towner RA; Jensen RL; Colman H; Vaillant B; Smith N; Casteel R; Saunders D; Gillespie DL; Silasi-Mansat R; Lupu F; Giles CB; Wren JD
Neurosurgery; 2013 Jan; 72(1):77-90; discussion 91. PubMed ID: 23096411
[TBL] [Abstract][Full Text] [Related]
10. Combined acetyl-11-keto-β-boswellic acid and radiation treatment inhibited glioblastoma tumor cells.
Conti S; Vexler A; Edry-Botzer L; Kalich-Philosoph L; Corn BW; Shtraus N; Meir Y; Hagoel L; Shtabsky A; Marmor S; Earon G; Lev-Ari S
PLoS One; 2018; 13(7):e0198627. PubMed ID: 29969452
[TBL] [Abstract][Full Text] [Related]
11. Anti-SEMA3A Antibody: A Novel Therapeutic Agent to Suppress Glioblastoma Tumor Growth.
Lee J; Shin YJ; Lee K; Cho HJ; Sa JK; Lee SY; Kim SH; Lee J; Yoon Y; Nam DH
Cancer Res Treat; 2018 Jul; 50(3):1009-1022. PubMed ID: 29129044
[TBL] [Abstract][Full Text] [Related]
12. Treatment with 5-azacitidine delay growth of glioblastoma xenografts: a potential new treatment approach for glioblastomas.
Kratzsch T; Kuhn SA; Joedicke A; Hanisch UK; Vajkoczy P; Hoffmann J; Fichtner I
J Cancer Res Clin Oncol; 2018 May; 144(5):809-819. PubMed ID: 29427211
[TBL] [Abstract][Full Text] [Related]
13. ELTD1 Review: New Regulator of Angiogenesis in Glioma.
Buzatu I; Tache DE; Manea Carneluti EV; Zlatian O
Curr Health Sci J; 2023; 49(4):495-502. PubMed ID: 38559823
[TBL] [Abstract][Full Text] [Related]
14. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
Mishima K; Johns TG; Luwor RB; Scott AM; Stockert E; Jungbluth AA; Ji XD; Suvarna P; Voland JR; Old LJ; Huang HJ; Cavenee WK
Cancer Res; 2001 Jul; 61(14):5349-54. PubMed ID: 11454673
[TBL] [Abstract][Full Text] [Related]
15. Loss of PLK2 induces acquired resistance to temozolomide in GBM via activation of notch signaling.
Alafate W; Xu D; Wu W; Xiang J; Ma X; Xie W; Bai X; Wang M; Wang J
J Exp Clin Cancer Res; 2020 Nov; 39(1):239. PubMed ID: 33176854
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo.
Onken J; Torka R; Korsing S; Radke J; Krementeskaia I; Nieminen M; Bai X; Ullrich A; Heppner F; Vajkoczy P
Oncotarget; 2016 Mar; 7(9):9876-89. PubMed ID: 26848524
[TBL] [Abstract][Full Text] [Related]
17. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
18. Silencing of epidermal growth factor, latrophilin and seven transmembrane domain-containing protein 1 (ELTD1) via siRNA-induced cell death in glioblastoma.
Serban F; Daianu O; Tataranu LG; Artene SA; Emami G; Georgescu AM; Alexandru O; Purcaru SO; Tache DE; Danciulescu MM; Sfredel V; Dricu A
J Immunoassay Immunochem; 2017; 38(1):21-33. PubMed ID: 27379831
[TBL] [Abstract][Full Text] [Related]
19. Anti-tissue factor (TF9-10H10) treatment reduces tumor cell invasiveness in a novel migratory glioma model.
Harter PN; Dützmann S; Drott U; Zachskorn C; Hattingen E; Capper D; Gessler F; Senft C; Seifert V; Plate KH; Kögel D; Mittelbronn M
Neuropathology; 2013 Oct; 33(5):515-25. PubMed ID: 23384223
[TBL] [Abstract][Full Text] [Related]
20. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice.
de Groot JF; Fuller G; Kumar AJ; Piao Y; Eterovic K; Ji Y; Conrad CA
Neuro Oncol; 2010 Mar; 12(3):233-42. PubMed ID: 20167811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
